References
- Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475–82. doi: 10.1164/rccm.200505-840OE
- Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183(11):1463–1471. doi: 10.1164/rccm.201009-1478CI
- ECFSPR Annual Report 2021, Zolin A, Orenti A, et al., 2023.
- Burgel PR, Bellis G, Olesen HV, et al. ERS/ECFS task force on provision of care for adults with cystic fibrosis in Europe. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015;46(1):133–141. doi: 10.1183/09031936.00196314
- Lopez A, Daly C, Vega-Hernandez G, et al. Elexacaftor/Tezacaftor/Ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607–614. doi: 10.1016/j.jcf.2023.02.004
- Burgel PR, Burnet E, Regard L, et al. The changing epidemiology of cystic fibrosis: the implications for adult care. Chest. 2023;163(1):89–99. doi: 10.1016/j.chest.2022.07.004
- Cystic Fibrosis Foundation. List of CFTR gene mutations that are responsive to Kalydeco® (ivacaftor). 2022 [cited 2024 Jan 13]. Available from: https://www.cff.org/sites/default/files/2022-02/Kalydeco-Approved-Mutations.pdf
- Cystic Fibrosis Foundation. List of CFTR gene mutations that are responsive to Symdeko® (tezacaftor/ivacaftor). 2022 [cited 2024 Jan 13]. Available from: https://www.cff.org/sites/default/files/2022-02/Symdeko-Approved-Mutations.pdf
- Cystic Fibrosis Foundation. List of CFTR Gene Mutations That Are Responsive to Trikafta® (elexacaftor/tezacaftor/ivacaftor). 2022 [cited 2024 Jan 13]. Available from : https://www.cff.org/sites/default/files/2022-02/Trikafta-Approved-Mutations.pdf
- Zampoli M, Morrow BM, Paul G. Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap! Front Pharmacol. 2023;14:1163391.
- Regard L, Lafoeste H, Martin C, et al. Ageing with cystic fibrosis: classical and emerging comorbidities in adults with cystic fibrosis. Rev Pneumol Clin. 2018;74(5):279–291. doi: 10.1016/j.pneumo.2018.09.012
- Ticona JH, Lapinel N, Wang J. Future comorbidities in an aging cystic fibrosis population. Life (Basel). 2023;13(6):1305. doi: 10.3390/life13061305
- Felipe A, Álvarez A, Traversi L. et al. Comorbidities in adult patients with Cystic fibrosis. Eur Respir J. 2023;62:OA1543. doi: 10.1183/13993003.congress-2023.OA1543
- Desai M, Hine C, Whitehouse JL, et al. Who are the 10%? - non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Respir med. 2022;199:106878. doi: 10.1016/j.rmed.2022.106878
- Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 1: pregnancy and lactation. Pediatr Pulmonol. 2023;58(12):3377–3385. doi: 10.1002/ppul.26706
- Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 2: Severe lung disease. Pediatr Pulmonol. 2023;58(12):3386–3392. doi: 10.1002/ppul.26698
- Kadouh NK, Elijah J, Fitzgerald LJ, et al. Use of CFTR modulators in special populations, part 3: solid organ transplant. Pediatr Pulmonol. 2023;58(12):3393–3402. doi: 10.1002/ppul.26396
- Hisert KB, Birket SE, Clancy JP, et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir Med. 2023;11(10):916–931. doi: 10.1016/S2213-2600(23)00324-7